Has Pfizer's "enterprise-wide cost realignment program," aimed primarily at optimizing its operational processes, as well as terminating clinical-stage projects where the commercial prospects of ...

With that in mind, let's consider two high-yield dividend stocks worth investing in: Pfizer (NYSE: PFE) and Medical ...

A raft of company earnings from the likes of Coca-Cola, General Motors, and Pfizer will determine if ... the Canadian election , capping a dramatic turnaround. Stocks to Watch: Noble reported ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Considering the analyst consensus, Pfizer's shares are currently trading below the consensus price target, suggesting some skepticism about near-term growth prospects. The positive news of the ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump’s planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and ...

Pfizer has been no stranger to acquisitions in recent years as a way to bolster its growth prospects. Its $43 billion acquisition of oncology company Seagen in 2023 showed it wasn't shying away ...

Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the failure of its obesity pill. The New York City-based drugmaker’s ...